Early fetal growth restriction: a new approach to guide the choice of management strategy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background: Fetal growth restriction (FGR) affects about 10 to 15% of all pregnancies. FGR is a potential cause of preterm birth, preeclampsia (PE), and stillbirth. FGR is associated with a high risk of adverse outcomes both in the neonatal period and long term. Aim: To identify the threshold of angiogenic markers (sFlt-1, PlGF, and their ratios) to predict fetal deterioration during early FGR. Materials and methods: This was a prospective study of 80 pregnant women. The study group included 45 patients with early FGR. FGR was diagnosed by a decrease in the estimated fetal weight (EFW) below the 10th percentile and impaired umbilical artery (UA) blood flow. Subgroup IA consisted of 24/45 (53.33%) pregnant women with a stable fetal condition according to Doppler and CTG monitoring, who progressed to full-term delivery. Subgroup IB included 21/45 (46.67%) patients with a progressive fetal deterioration, including an increase in PI up to the absence of end-diastolic blood flow in the UA, a decrease in cerebro-placental ratio and a reduction in PI in MCA, no increase in fetometric ultrasound parameters, and questionable or pathological type of CTG. Results: In subgroup IA, sFlt-1and PlGF concentrations and sFlt-1/PlGF ratio were 54305 pg/ml, 82.67pg/ml, and 852.44, respectively. In subgroup IB, sFlt-1and PlGF concentrations and sFlt-1/PlGF ratio were 105001pg/ ml, 34.89 pg/ml, and 2888.92, respectively. Concentrations of sFlt-1, PlGF, and sFlt-1/PlGF in pregnant women with a healthy pregnancy were 11860 pg/ml, 705 pg/ml, and 19.1, respectively. The optimal cut-off values of PlGF and sFlt-1/PlGF were 52.7 pg/ml. and 1118.12. Conclusion: The study findings showed that patients in the two subgroups of early FGR had statistically significant different levels of angiogenic markers. PlGF level ≥ 52.7 pg/ml and/or sFlt-1/lGF ratio ≥ 1118.12 were predictive for a high risk of fetal deterioration and adverse perinatal outcomes. Our study showed the validity of using the studied angiogenic markers in pregnant women with early FGR. The findings support a recommendation to use these markers in clinical practice.

全文:

受限制的访问

作者简介

Elena Timokhina

I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenov University)

Email: elena.timokhina@mail.ru
Dr. Med. Sci., Professor at the Department of Obstetrics, Gynecology and Perinatology 119991, Russia, Moscow, B. Pirogovskaya str., 2-4

Alexander Strizhakov

I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenov University)

Email: kafedra-agp@mailru
Academician of the RAS, Professor, Head of the Department of Obstetrics, Gynecology and Perinatology 119991, Russia, Moscow, B. Pirogovskaya str., 2-4

Nicoleta Zafiridi

I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenov University)

Email: zafiridisniki@mail.ru
PhD. Student at the Department of Obstetrics, Gynecology and Perinatology 119991, Russia, Moscow, B. Pirogovskaya str., 2-4

Irina Fedyunina

I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenov University)

Email: irina.fedjunina@mail.ru
Ph.D., Teaching Assistant at the Department of Obstetrics, Gynecology and Perinatology 119991, Russia, Moscow, B. Pirogovskaya str., 2-4

Alexander Aslanov

I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenov University)

Email: aslanov7@bk.ru
Ph.D., Associate Professor at the Department of Obstetrics, Gynecology and Perinatology 119991, Russia, Moscow, B. Pirogovskaya str., 2-4

参考

  1. Friedman A.M., Cleary K.L. Prediction and prevention of ischemic placental disease. Semin. Perinatol. 2014; 38(3): 177-82. https://dx.doi.org/10.1053/j.semperi.2014.03.002.
  2. ACOG Practice bulletin no. 134: fetal growth restriction. Obstet. Gynecol. 2013; 121(5): 1122-33. https://dx.doi.org/10.1097/01.AOG.0000429658.85846.f9.
  3. Hunt K., Kennedy S.H., Vatish M. Definitions and reporting of placental insufficiency in biomedical journals: a review of the literature. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016; 205: 146-9. https://dx.doi.org/10.1016/j.ejogrb.2016.08.029.
  4. Тимохина Е.В., Стрижаков А.Н., Зафириди Н.В., Губанова Е.С. Инновационный подход к прогнозированию и терапии преэклампсии -мировой опыт. Акушерство и гинекология. 2019; 5: 5-10. https://dx.doi.org/10.18565/aig.2019.5.5-10.
  5. Halliday H.L. Neonatal management and long-term sequelae. Best Pract. Res. Clin. Obstet. Gynaecol. 2009; 23(6): 871-80. https://dx.doi.org/10.1016/j.bpobgyn.2009.06.005.
  6. Mendez-Figueroa H., Truong V.T., Pedroza C., Chauhan S.P. Morbidity and mortality in small-for-gestational-age infants: A Secondary Analysis of Nine MFMU Network Studies. Am. J. Perinatol. 2017; 34(4): 323-32. https://dx.doi.org/10.1055/s-0036-1586502.
  7. Bakalis S., Peeva G., Gonzalez R., Poon L.C., Nicolaides K.H. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks. Ultrasound Obstet. Gynecol. 2015; 46(4): 446-51. https://dx.doi.org/10.1002/uog.14863.
  8. Birdir C., Fryze J., Frolich S., Schmidt M., Koninger A., Kimmig R. et al. Impact of maternal serum levels of Visfatin, AFP, PAPP-A, sFlt-1 and PlGF at 11-13 weeks gestation on small for gestational age births. J. Matern. Fetal Neonatal Med. 2017; 30(6): 629-34. https://dx.doi.org/10.1080/14767058.2016.1182483.
  9. Hagmann H., Thadhani R., Benzing T., Karumanchi S.A., Stepan H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin. Chem. 2012; 58(5): 837-45. https://dx.doi.org/10.1373/clinchem.2011.169094.
  10. Burton G.J., Woods A.W., Jauniaux E., Kingdom J.C. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009; 30(6): 47382. https://dx.doi.org/10.1016/j.placenta.2009.02.009.
  11. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003; 111(5): 649-58. https://dx.doi.org/10.1172/JCI17189.
  12. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 2013; 153(1): 13-9. https://dx.doi.org/10.1093/jb/mvs136.
  13. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A. C., Sennstrom M. et al. Predictive value of the sFlt-1 :PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 2016; 374(1): 13-22. https://dx.doi.org/10.1056/NEJMoa1414838.
  14. Макаров О.В.,Волкова Е.В.,Лысюк Е.Ю., Копылова Ю.В. Фетоплацентарный ангиогенез у беременных с плацентарной недостаточностью. Акушерство, гинекология и репродукция. 2013; 7(3): 13-9.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021